Diabetic Macular Edema Drug Pipeline — PatSnap Eureka
Diabetic Macular Edema Drug Pipeline: Anti-VEGF, Gene Therapy & Kinase Inhibitor Approaches
DME affects approximately one in fourteen people with diabetes globally. The therapeutic landscape is rapidly evolving beyond standard intravitreal anti-VEGF monotherapy toward high-dose extended-interval regimens, gene therapy, dual-pathway biologics, and small molecule kinase inhibitors — with 30–40% of patients showing insufficient response to current standard of care.
VEGF-Driven Pathology and Emerging Molecular Targets in DME
Retrieved results consistently identify VEGF as the primary molecular driver of DME pathology. Breakdown of the inner and outer blood-retinal barriers leads to macular swelling, with capillary degeneration, pericyte loss, and retinal ischemia progressing to the neovascular stage of proliferative diabetic retinopathy (PDR). VEGF isoforms are documented as the primary vasoformative and permeability factors underlying both DME and PDR.
Beyond VEGF, patent evidence retrieved via PatSnap's analytics platform highlights several additional molecular targets driving next-generation combination strategies. Angiopoietin-2 (ANG2) is positioned as a co-driver of vascular destabilization — a rational combination target with VEGF blockade. Plasma kallikrein is established as a VEGF-independent mechanism of retinal vascular permeability relevant to DME, providing rationale for small molecule inhibitors as a distinct therapeutic modality.
Emerging targets include the complement pathway (relevant for treatment-refractory subpopulations), mTOR/PI3K signaling downstream of multiple growth factor receptors, PDGF for pericyte stabilization, ceramide for sphingolipid-driven vascular dysfunction, and the novel NUP153 nuclear pore protein implicated in pro-angiogenic mRNA export. The WIPO patent database reflects an expanding target landscape well beyond VEGF monotherapy.
Four Dimensions of DME Pipeline Innovation
Patent and literature evidence retrieved from PatSnap Eureka spans high-dose anti-VEGF biologics, gene therapy, small molecule kinase inhibitors, and bispecific multi-target biologics — each addressing distinct limitations of current standard of care.
High-Dose Extended-Interval Anti-VEGF (Aflibercept 8 mg)
The largest single cluster in this dataset — more than 15 patent filings from Bayer Healthcare LLC alone, spanning 12+ jurisdictions — centers on 8 mg aflibercept administered at extended intravitreal intervals (HDq12, HDq16, HDq20). The mechanism involves VEGFR1/VEGFR2 extracellular domain fusion trapping free VEGF-A, PlGF, and VEGF-B. Pharmacokinetic modeling shows free aflibercept reaching its lower limit of quantitation approximately 15 weeks post-injection — the pharmacological basis for extended intervals. Regeneron holds a parallel multi-jurisdictional portfolio on 2 mg aflibercept q8/q16 regimens.
Clinical stage · 12+ jurisdictionsGene Therapy-Based Sustained Anti-VEGF Delivery
Three distinct gene therapy strategies appear in the dataset. RegenxBio Inc. discloses rAAV vector approaches delivering anti-hVEGF antigen-binding fragments (Fabs) via subretinal, suprachoroidal, and external scleral routes. Adverum Biotechnologies discloses rAAV2 variant particles encoding an aflibercept-like polypeptide as a single intravitreal unit dose targeting reduction of central subfoveal thickness (CST) fluctuation. A third approach from Regenerative Biology Inc. delivers HuPTM anti-hVEGF Fabs with α2,6-sialylation via suprachoroidal expression vectors.
Preclinical to early clinicalSmall Molecule Kinase Inhibitors & RTK Inhibitors
Six distinct small molecule approaches are represented: selective RTK inhibitors (Alcon Inc.), photoinducible azide-containing kinase inhibitors activated by intraocular light (Semmelweis University, 2025 WO), mTOR inhibitors including rapamycin/sirolimus (Santen Pharmaceutical), PI3K/mTOR dual inhibitor gedatolisib (Celcuity Inc., 2025 WO), plasma kallikrein inhibitor (KalVista Pharmaceuticals), and vicanabine — a triazolopyrimidine compound (Hoffmann-La Roche, 2025 CN). Recent 2025 filings from Celcuity, Roche, and Semmelweis signal renewed small molecule innovation interest.
Preclinical to Phase 2Bispecific & Multi-Target Biologics
Multi-target biologic strategies address the approximately 60–70% of DME patients with incomplete anti-VEGF response. F. Hoffmann-La Roche AG discloses antibodies binding both VEGF and ANG2. Innovent Biologics discloses efdamrofusp alfa — a fusion protein inhibiting both VEGF and complement pathways (2025 WO). Daifu Medical LLC discloses a bispecific aptamer targeting VEGF, IL-8, and ANG2 simultaneously. The (OSI) Eye Tech Company patent demonstrates preclinical combination of PDGF antagonist with VEGF antagonist showing synergistic vessel regression.
Preclinical to emerging clinicalDME Pipeline: Key Data Visualised
Patent filing data and clinical response metrics derived from PatSnap Eureka dataset analysis, illustrating the unmet need driving pipeline diversification.
Anti-VEGF Monotherapy Response Rates in DME
Only 29% of DME patients achieve BCVA improvement at 2 years; 30–40% show insufficient response — the core unmet need driving multi-target pipeline innovation.
Patent Filing Volume by Key DME Assignee
Bayer Healthcare LLC leads with 15+ filings for 8 mg aflibercept. Regeneron, Roche, RegenxBio, and Adverum represent the next tier of IP activity in this dataset.
Key Organisations Driving DME Patent Activity
Commercial IP activity is concentrated among a small number of major pharmaceutical and biotechnology organisations. Academic institutions are active at preclinical stage.
| Assignee | Key Technology | Target(s) | Jurisdictions | Stage Signal |
|---|---|---|---|---|
| Bayer Healthcare LLC | 8 mg aflibercept HDq12/16/20 extended-interval regimens | VEGF-APlGFVEGF-B | US, EP, WO, JP, AU, CA, NZ, KR, TW, BR, ID, CN (12+) | Post-Phase 3 |
| Regeneron Pharmaceuticals | 2 mg aflibercept q8/q16 DRSS endpoint regimens | VEGF-APlGF | US, KR, JP, BR, AU, SG, NZ, CA, ID | Phase 3 / Approved |
| F. Hoffmann-La Roche AG | VEGF/ANG2 bispecific antibody; vicanabine small molecule | VEGFANG2 | CA, MX, CN | Clinical / Emerging |
| RegenxBio Inc. | rAAV-anti-VEGF Fab gene therapy (subretinal/suprachoroidal) | VEGF | MX, BR, JP, KR | IND-enabling / Early Clinical |
| Adverum Biotechnologies | rAAV2-aflibercept single intravitreal unit dose | VEGF | SG, BR | Early Clinical |
Track DME IP across all assignees and jurisdictions
PatSnap Eureka monitors new filings, status changes, and freedom-to-operate signals in real time.
What the DME Patent Landscape Signals for IP Strategy
Key strategic takeaways derived from patent and literature evidence in the PatSnap Eureka dataset — relevant for IP strategists, R&D teams, and competitive intelligence functions.
Bayer's 8 mg Aflibercept IP Cluster Dominates the Commercial Signal
Bayer Healthcare LLC's multi-jurisdictional patent prosecution covering 8 mg aflibercept HDq12/16/20 regimens, with filings spanning at least 12 jurisdictions, represents an active effort to establish IP dominance over next-generation standard-of-care dosing. IP strategists should map freedom-to-operate carefully around VEGFR fusion protein dosing claims.
Gene Therapy as Sustained Delivery: Strategically Important but Early Stage
Activity from Adverum Biotechnologies and RegenxBio is predominantly in preclinical-to-early clinical jurisdictions. The promise of single-administration therapy is significant for patient compliance, but IP around AAV capsid engineering and transgene expression will be critical battlegrounds. The Adverum filing specifically targets reduction of CST fluctuation — a limitation of episodic protein injection.
Clinical Signals from the DME Patent & Literature Dataset
The Bayer Healthcare LLC patent family describes specific pharmacokinetic modeling (free aflibercept clearance ~0.3–0.46 mL/day; LLOQ in ocular compartment ~15 weeks post-IVT) and references to "safe and effective" IVT injection claims with "at least similar functional and potentially improved anatomic outcomes" compared to the 2 mg regimen — language consistent with completed Phase 3 clinical trial data. The filing dates (2022–2025) and multi-jurisdictional prosecution are consistent with a post-Phase 3 regulatory submission period.
Regeneron's filings explicitly reference the FDA-recognised Diabetic Retinopathy Severity Scale (DRSS) as a clinical endpoint, specifying ≥2-step DRSS improvement criteria and citing specific patient demographics (mean HbA1c ~8.5%, mean BCVA ~82 ETDRS letters, mean CRT ~247 µm) consistent with reported Phase 3 PANORAMA study patient characteristics.
A multicentre study from 27 UK-NHS centres (5,716 NPDR eyes) provides real-world clinical data on the impact of repeated anti-VEGF injections on PDR development, modelled using Cox regression and propensity score matching — direct clinical evidence that anti-VEGF injections reduce PDR risk in routine care. PatSnap's life sciences intelligence platform surfaces these clinical-patent linkages automatically.
No clinical data for gene therapy (RegenxBio, Adverum), anti-ceramide antibodies, bispecific aptamers, or most novel small molecule approaches were identified in the retrieved results — confirming these modalities remain at preclinical or early investigational stage.
Active Combination Strategies and Emerging Pipeline Directions
Retrieved results signal several active combination and emerging-direction strategies addressing the limitations of anti-VEGF monotherapy, as documented in PatSnap customer research and the global patent record.
VEGF + PDGF Dual Blockade
The (OSI) Eye Tech Company patent (2012, CN) demonstrates preclinical combination of PDGF antagonist (Gleevec/imatinib analog) with VEGF antagonist (pegaptanib/Macugen) in laser-induced CNV models, showing synergistic vessel regression. Pericyte stabilization via PDGF blockade combined with VEGF neutralization addresses the anatomical limitations of VEGF monotherapy.
Preclinical · Pericyte stabilizationVEGF + Complement Pathway (efdamrofusp alfa)
Innovent Biologics' efdamrofusp alfa (2025, WO) represents the most recent and clinically advanced dual-pathway signal in this dataset, targeting both complement-mediated inflammation and VEGF-driven neovascularization in a single fusion protein for DME. This approach is particularly relevant for treatment-refractory subpopulations where complement activation is a co-pathogenic mechanism.
Emerging clinical · WO, AUMulti-Target Aptamer (VEGF + IL-8 + ANG2)
The Daifu Medical bispecific aptamer (VEGF + IL-8 + ANG2, 2023, CN) signals emerging Chinese IP interest in multi-target aptamer formats. The approach is motivated by the observation that anti-VEGF monotherapy is only effective in approximately 30–40% of DME patients — meaning the approximately 60–70% of patients with incomplete anti-VEGF response represent the target population for this trispecific platform.
Preclinical · CN filing · Multi-targetPhotoactivatable Intravitreal Kinase Inhibitors
The Semmelweis University WO filing (2025) describes light-activated covalent kinase inhibitors — a highly novel platform concept exploiting retinal light transmission for spatially selective target engagement. Azide-containing photoactivatable kinase inhibitors are designed to be covalently activated by intraocular light, providing spatially selective VEGF signaling modulation. The stage is preclinical and the approach is mechanistically early.
Preclinical · Novel platform · WO 2025Diabetic Macular Edema Drug Pipeline — key questions answered
VEGF is the primary molecular driver of DME pathology. Breakdown of the inner and outer blood-retinal barriers leads to macular swelling, with capillary degeneration, pericyte loss, and retinal ischemia progressing to the neovascular stage of proliferative diabetic retinopathy. VEGF isoforms are documented as the primary vasoformative and permeability factors underlying both DME and PDR.
Retrieved results document that only 29% of DME patients achieve BCVA improvement after two years of anti-VEGF therapy, and that 30–40% show insufficient response to current anti-VEGF monotherapy — motivating the multi-target strategies described in this report.
The 8 mg dose of aflibercept is administered at extended intravitreal intervals (HDq12, HDq16, HDq20 dosing regimens: maintenance doses every 12, 16, or 20 weeks) following an initial loading phase. The mechanism involves VEGFR1/VEGFR2 extracellular domain fusion trapping free VEGF-A, PlGF, and VEGF-B in the vitreous compartment, with ocular pharmacokinetic modeling showing free aflibercept reaching its lower limit of quantitation approximately 15 weeks post-injection — the pharmacological basis for extended intervals.
Three distinct gene therapy strategies appear in the dataset: AAV-mediated anti-VEGF Fab delivery (RegenxBio Inc.), AAV2-aflibercept gene therapy (Adverum Biotechnologies, Inc.), and fully human post-translationally modified (HuPTM) antibody gene therapy delivering anti-hVEGF Fabs with α2,6-sialylation via suprachoroidal or subretinal expression vectors (Regenerative Biology Inc.).
Key multi-target biologic strategies include: VEGF + ANG2 dual inhibition (F. Hoffmann-La Roche AG bispecific antibody), VEGF + Complement dual inhibition (Innovent Biologics' efdamrofusp alfa fusion protein), and a VEGF + IL-8 + ANG2 trispecific aptamer (Daifu Medical LLC), motivated by the observation that anti-VEGF monotherapy is only effective in approximately 30–40% of DME patients.
Small molecule kinase inhibitor approaches include: selective RTK inhibitors (Alcon Inc.), photoinducible azide-containing kinase inhibitors activated by intraocular light (Semmelweis University), mTOR inhibitors including rapamycin/sirolimus (Santen Pharmaceutical), PI3K/mTOR dual inhibitor gedatolisib (Celcuity Inc.), oral plasma kallikrein inhibitor (KalVista Pharmaceuticals), and vicanabine, a triazolopyrimidine compound (Hoffmann-La Roche).
Still have questions about the DME pipeline? Let PatSnap Eureka search patents and research for you.
Ask Eureka AI About DME PipelineAccelerate Your DME Drug Pipeline Research with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map therapeutic landscapes, identify freedom-to-operate risks, and track emerging assignees across the DME pipeline.
References
- Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders — Bayer Healthcare LLC, 2023, US [Patent]
- Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders — Bayer Healthcare LLC, 2023, EP [Patent]
- Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders — Bayer Healthcare LLC, 2023, WO [Patent]
- Use of a VEGF antagonist to treat angiogenic eye disorders — Regeneron Pharmaceuticals, Inc., 2020, SG [Patent]
- Use of VEGF Antagonists to Treat Angiogenic Eye Disorders — Regeneron Pharmaceuticals, Inc., 2021, ID [Patent]
- Treatment of ocular diseases using recombinant viral vectors encoding anti-VEGF FABs — RegenxBio Inc., 2025, JP [Patent]
- Gene therapy for eye pathologies — RegenxBio Inc., 2021, MX [Patent]
- Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept — Adverum Biotechnologies, Inc., 2022, SG [Patent]
- Method for reducing CST fluctuation in neovascular AMD caused by a recombinant adenoassociated virus — Adverum Biotechnologies, Inc., 2024, BR [Patent]
- Treating diabetic retinopathy with fully human post-translationally modified anti-VEGF Fab — Regenerative Biology Inc., 2022, CN [Patent]
- Novel photoinducible kinase inhibitors for treating proliferative and vasoproliferative diseases — Semmelweis University, 2025, WO [Patent]
- Treatment of ocular diseases using gedatolisib (PI3K/mTOR inhibitor) — Celcuity Inc., 2025, WO [Patent]
- Methods of treating age-related macular degeneration and diabetic macular edema (efdamrofusp alfa) — Innovent Biologics (Suzhou) Co., Ltd., 2025, WO [Patent]
- Personalized treatment of ophthalmologic diseases (VEGF/ANG2 bispecific) — F. Hoffmann-La Roche AG, 2021, CA [Patent]
- Bispecific aptamer compositions for treating retinal diseases (VEGF + IL-8 + ANG2) — Daifu Medical LLC, 2023, CN [Patent]
- Treatments of diabetic macular edema and impaired visual acuity (plasma kallikrein inhibitor) — KalVista Pharmaceuticals Limited, 2022, IL [Patent]
- mTOR pathway inhibitors for treating ocular disorders — Santen Pharmaceutical Co., Ltd., 2012, US [Patent]
- WIPO — World Intellectual Property Organization: Global Patent Database
- National Eye Institute (NIH) — Diabetic Eye Disease Research
- U.S. Food and Drug Administration — Ophthalmology Drug Approvals
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.